Lower urinary tract symptoms and benign prostatic hyperplasia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

References

  1. Избранные главы гериатрической урологии / Под общ. ред. Л.М. Гориловского. М.: Ньюдиамед, 2000. 374 с.
  2. Мартов А.Г., Корниенко С.И., Гущин Б.Л. и др. Интраоперационные осложнения при трансуретральных оперативных вмешательствах по поводу доброкачественной гиперплазии предстательной (ТУР) железы. Урология. 2005. С. 3-8.
  3. Руководство по урологии. В 3 т. / Под общ. ред. Н.А. Лопаткина. М.: Медицина, 1998. Т. 3.
  4. Abrams Р.Н., Farrar D.J., Tumer-Warwick R.T. et al. The results of prostatectomy: A symptomatic and urodynamic analysis of 152 patients. J. Urol. 1979; 121:640-642.
  5. Ahmed M., Bell T., Lawrence W.T. et al. Transurethral microwave thermotherapy (Prostatron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: A randomized controlled parallel study. Br J Urol. 1997; 79: 181-185.
  6. Alsikafi N.F., Gerber G.S. Bilateral metachronous testicular seminoma associated with microlithiasis. J. Urol. 1998; 159: 1643-1644.
  7. Barry M.J. Prostate specific antigen. Testing for early diagnosis of prostate cancer. N Eng J Med. 2001; 344: 1373-1377.
  8. Barry M.J., Fowler F.J. Jr., O’Leary M.P. et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 1992; 148: 1549-1557.
  9. Blanker M.H., Bohnen A.M., Groeneveld F.P. et al. Normal voiding pattemsand determinants of increased diurnal and nocturnal voiding frequency in elderlymen. J. Urol. 2000; 164: 1201-1205.
  10. Boyle P. Epidemiology of benign prostatic hyperplasia: risk factors andconcomitance with hypertension. Br J Clin. Pract. 1994; 74: 18-22.
  11. Boyle P., Robertson C., Lowe E., Roehbom C. Meta-analysis of clinical trials of Permixon in the treatment of benign prostatic hyperplasia. Urology. 2000; 55: 533-539.
  12. Brawer М.К. Diagnosis of lower urinary tract symptoms. Postgrad. Med. Special. Report. 1999. P. 7-10.
  13. Cecil R.L. Cecil Textbook of Medicine. 20-th ed. Philadelphia: WBSaunders. 1996. 2233 p.
  14. Craigen A., Hickling J., Saunders C., Carpenter R. The natural history of prostatic obstruction: A prospective survey. J.R. Coll. Gen. Pract. 1969; 18: 226-232.
  15. Djavan B., Roehrbom C.G., Shariat S. et al. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. J. Urol. 1999; 161: 139-143.
  16. Flanigan R.C., Reda D.J., Wasson J.H. et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A Department of Veterans Aff airs Cooperative Study. J. Urol. 1998; 160: 12-16.
  17. Francisca E.A., d’Ancona F.C., Meuleman E.J. et al. Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J. Urol. 1999; 161: 486-490.
  18. Gerber G.S. Benign prostatic hyperplasia in older men. Clin. Geriatr. Med. 1998; 14: 317-331.
  19. Girman C.J., Jacobsen S.J., Guess H.A. et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow. J. Urol. 1995; 153: 1510-1515.
  20. Gormley G.J., Stoner E., Bruskewitz R.C. et al. The effect of fmasteridem men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng. J. Med. 1992; 327: 1185-1191.
  21. Guess H.A. Epidemiology and natural history off benign prostatic hyperplasia. Urol. Clin. North. Am. 1995; 22: 247-261.
  22. Hoffman R.M., MacDonald R., Wilt T.J. Laser prostatectomy for benign prostatic obstruction (Cochrane Review). The Cochrane Library. 2004; 1: 24.
  23. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate. 1989; 2: 33-50.
  24. Jensen K.M.-E. Clinical evaluation of routine urodynamic investigations in prostatism. Neurourol. Urodynam. 1989; 8: 545-578.
  25. Kirby R., Boyle P., Fitzpatrick J. et al. Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media, 1996. P. 125-135.
  26. Lepor H., Williford W.O., Barry M.J. et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Aff airs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Eng. J Med. 1996; 335: 533-539.
  27. Lepor H., Williford W. O., Barry M. J. et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol. 1998; 160: 1358-1367.
  28. Lowe F.C., Fagelman E. Phytotherapy in the treatment of benign prostatic- hyperplasia: an update. Urology. 1999; 53: 671-678.
  29. Matthiesen T.B., Rittig S., Mortensen J.T., Djurhuus J.C. Nocturia and polyuria in men referred with lower urinary tract symptoms, assessed using a 7-day frequency volume chart. Br J. Urol. Int. 1999; 83: 1017-1022.
  30. Medina J.J., Parra R.O., Moore R.G. Benign prostatic hyperplasia (the aging prostate) // Med Clin North Am. 1999; 83: 1213-1229.
  31. Meyhofl H.H., Ingemann L., Nordling J., Hald T. Accuracy in preoperative estimation of prostatic size. A comparative evaluation of rectal palpation, intravenous pyelography, urethral closure pressure profile recording and cystourethros copy. Scand J Urol Nephrol. 1981; 15: 45-51.
  32. Neal D.E., Ramsden P.D., Sharpies L. et al. Outcome of elective prostatectomy. BMJ. 1989; 299: 762-767.
  33. Neal D.E., Styles R.A., Powell P.H. et al. Relationship between voiding pressure, symptoms and urodynamic findings in 253 men undergoing prostatectomy. Br J Urol. 1987; 60: 554-559.
  34. Nyman MA., Schwenk N.M., Silverstein M.D. Management of urinaryretention: rapid versus gradual decompression and risk of complications. Mayo Clin Proc. 1997; 72: 951-956.
  35. Riehmann M., Knes J.M., Heisey D. et al. Transurethral resection versusincision of the prostate: a randomized, prospective study. Urology. 1995; 45: 768-775.
  36. Roehrbom C.G., Preminger G., Newhall P. et al. Microwave ther motherapy for benign prostatic hyperplasia with the Domier Urowave: Results of a randomized double-blind multicenter sham-controlled trial. Urology. 1998; 51: 19-28.
  37. Rowan D., James E.D., Kramer AE. et al. Urodynamic equipment: technical aspects. Produced by the International Continence Society Working Party on Urodynamic Equipment. J Med Eng Technol. 1987; 11: 57-64.
  38. Shingleton W.B., Farabaugh P., May W. Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia. Urology. 2002; 60: 305-308.
  39. Toscano I.L., Maciel L. C., Martins F.G. et al. Transurethral resection of the prostate: Prospective randomized study of catheter removal after 24 or 48 hours following surgery. Braz J Urol. 2001; 27: 144- 147.
  40. Van Melick H.H., Van Venrooij G.E., Eckhardt M. D et al. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: urodynamic effects. J. Urol. 2002; 168: 1058-1062.
  41. Van Venrooij G.E., Eckhardt M.D,, Gisholf K.W., Boon T.A. Data from frequency-volume charts versus symptom scores and quality of life score in menwith lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 2001; 39: 42-47.
  42. Wagrell L., Schelin S., Nordling J. et al. Feedback microwave ther motherapy versus TURP for clinical BPH: A randomized controlled multicenter study. Urology. 2002; 60: 292-299.
  43. Wasson J., Reda D., Bmskewitz R.C. et al. A comparison of tiansurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Eng J Med. 1994; 334: 75-79.
  44. Wilde M.I., Goa K.L. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs. 1999; 57: 557-581.
  45. Wilt T., Ishani A., MacDonald R. Serenoa repens for benign prostatic hyperplasia (Cochrane Review). The Cochrane Library. 2004; 1: 24.
  46. Montorsi F. Summary of product characteristics. Eur. Urol. 2010; 9: 491-495.
  47. http://uroweb.otg/guideline/treatment-of-non-neurogenic-male-luts/
  48. Roehrbom C.G. et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999; 53: 581-589.
  49. Boyle P. et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology. 2001; 58: 717-722.
  50. Roehrbom C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57: 123-131.
  51. Giuliano F. et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013; 63: 506-616.
  52. Morelli A. et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J. Sex. Med. 2011; 8: 2746-2760.
  53. Vignozzi L. et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013; 73: 1391-1402.
  54. Ahyai SA. et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010; 58: 384-397.
  55. Madersbacher S. et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol. 2005; 47: 499-504.
  56. Reich O. et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J. Urol. 2008; 180: 246-249.
  57. Madersbacher S., et al. Is transurethral resection of the prostate still justified. BJU Int. 1999; 83: 227-237.
  58. Naspro R. et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. Eur Urol. 2006; 50: 563-568.
  59. Skolarikos A. et al. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J. Endourol. 2008; 22: 2333-2340.
  60. Boyle P. et al. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int. 2004; 94: 83-88.
  61. Armitage J.N. et al. Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J. Urol. 2007; 177: 1619-1624.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies